Drug testing drives phase advancement, sanctions, and terminations. When a result is wrong or misread, the consequence lands on a participant anyway. ToxiPharm helps programs build testing protocols that are defensible and train staff to read results correctly.
These are the recurring issues behind contested results in problem-solving courts and community supervision. Most are avoidable with the right protocol and a staff that knows what a screen can and cannot tell them.
Point-of-care and laboratory immunoassay screens are presumptive. They cross-react with prescribed and over-the-counter medications, and a positive alone does not establish use. Programs that sanction before confirmatory LC-MS/MS testing are exposed on both fairness and defensibility grounds.
A chronic cannabis user can test positive for weeks after genuine abstinence. Without creatinine normalization and a series of results, a program cannot distinguish new use from residual excretion, and participants get sanctioned for a decline that is actually consistent with cessation.
EtG confirms alcohol exposure, not necessarily drinking. Hand sanitizer, mouthwash, and some foods and medications produce low-level positives. Programs using a single cutoff without context can and do sanction on incidental exposure.
Standard panels do not detect medetomidine, xylazine, nitazenes, or designer benzodiazepines. A clean screen can coexist with a serious exposure, which affects both safety decisions and how a program interprets participant self-report.
Matrix selection, panel composition, cutoff levels, confirmation triggers, and testing frequency, reviewed against NADCP Adult Drug Court Best Practice Standards and current laboratory practice.
Practical training for coordinators, case managers, probation officers, and judicial staff on what a screen means, when confirmation is required, and how to read a result in context.
Case review when a participant disputes a result, and testimony in sanction, violation, and termination proceedings. Drug court is the primary area of testimony experience.
These are already built and free to use. Programs may print and distribute the patient alerts to participants.
Check whether a medication explains a positive, look up a detection window, or work through a cannabis excretion series before a sanction hearing.
Open the tools →Printable alerts on medetomidine, nitazenes, and cychlorphine, written for participants rather than clinicians, with wallet cards for distribution.
View patient alerts →Most programs have never had their testing protocol reviewed by a toxicologist. If you are sanctioning on results, it is worth knowing whether those results support what you are concluding from them.
The clinical toxicology newsletter: drug trends, regulatory updates, and practice-relevant science, delivered free.
No spam. Unsubscribe anytime.